Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Make your choice for the PS5 game that you love playing with companions! - 2What you need to know about Trump accounts as Michael and Susan Dell donate $6 billion to the new early childhood investment program
- 3German journalists' union condemns attack on reporters in village
- 4No injuries after blast at pro-Israel centre in the Netherlands
- 5Warning for snow and ice extended
- Burger King launches 'SpongeBob' menu ahead of film's release. A look at the Bikini Bottom-inspired meal, plus what taste testers are saying.
- The Best Portable Applications for Psychological wellness and Prosperity
- Internet Bookkeeping Programming for Consultants
- Iran war pushes Germany's deficit to 4.2% as growth outlook is cut by 50%
- Thousands of genomes reveal the wild wolf genes in most dogs’ DNA
- Brazil's former President Jair Bolsonaro seeks house arrest for prison time citing health issues
- Fundamental Home Machines for Improved Solace in Summer
- The most effective method to Pick the Ideal Lab Precious stone Wedding band
- See a half-lit moon shine among the stars of Aquarius on Nov. 27
